New visit to People Republic of China

By | 2017, News | No Comments

During the last week of April, our colleagues Dr. Oscar Ahumada and Rosalía Calleja visited People Republic China again. This time, a really tight agenda was waiting for them, as well as one demo-machine SCALA mini sent some weeks ago. The demo-platform will help us to promote our technology in China, as well as introduce the new SCALA mini into the International market.

They had the opportunity of visiting some potential customers as Beijing Institute of Semiconductors (CAS), Changchun Institute of Applied Chemistry and at University of Science and Technology of China in Hefei. Making a demo to these scientists will help us to better make understood our technology; and show the awesome capabilities of this instrument for MEMS characterization.

Last publication about HIV detection receives huge media coverage

By | 2017, Media, News | No Comments

Major national and international newspapers, radio, tv and online sources have echoed the last research from Bionanomechanics Lab about HIV detection within a week of infection.

The technology, patented by CSIC and licensed to Mecwins, is also being applied in the early detection of some types of cancer.

Due to the huge media coverage of the results, we have selected just a few links for further information:

Developing a biosensor for detecting HIV at first week after infection

By | 2017, News, Publications | No Comments

Early detection of HIV infection is the best way to prevent spread of the disease and to improve the efficiency of the antiretroviral therapy. Nucleic acid amplification tests (NAAT) have become the gold-standard for detecting low-concentrations of the virus in blood. However, these methods are technically demanding and cost-prohibitive in developing countries. Immunoassays are more affordable and can be more easily adapted for point-of-care diagnosis. However, the sensitivity so far of these methods has been too low. The research, published on February 15th in the journal PLOS ONE, reports the development of a sandwich immunoassay that combines nanomechanical and optoplasmonic transduction methods for detecting the HIV-1 capsid antigen p24 in human serum. The immunoreactions take place on the surface of a compliant microcantilever where gold nanoparticles are used as both mechanical and plasmonic labels. The microcantilever acts as both a mechanical resonator and an optical cavity for the transduction of the mechanical and plasmonic signals. The limit of detection of the immunoassay is 10−17 g/mL that is equivalent to one virion in 10 mL of plasma. This is 5 orders of magnitude better than last generation of approved immunoassays and 2 orders of magnitude better than NAAT. This technology meets the demands to be produced en masse at low cost and the capability for miniaturization to be used at the point-of-care.

journal.pone.0171899.g001

Schematic representation of the p24 sandwich immunoassay.

(a) The top surface of the cantilever is functionalized with capture antibodies against HIV-1 p24 antigen (top schematic). Antifouling molecules are immobilized on the bottom surface of the cantilever and voids between the antibodies to minimize nonspecific interactions. The cantilever is then immersed in the human serum sample to allow specific binding of p24 to the cantilever surface (middle schematic). Finally, the p24 antigen captured on the cantilever is specifically linked to 100-nm-diameter gold nanoparticles that carry detection antibodies. (b) Scanning electron microscopy image of the silicon microcantilever arrays used in this work. (c). Schematics of the 96-well microtiter plate format, in which the immunoassays were carried out

Source: Kosaka PM, Pini V, Calleja M, Tamayo J (2017) Ultrasensitive detection of HIV-1 p24 antigen by a hybrid nanomechanical-optoplasmonic platform with potential for detecting HIV-1 at first week after infection. PLoS ONE 12(2): e0171899. doi:10.1371/journal.pone.0171899

You can access to the publication in PLOS ONE journal by clicking here.

NEW VISIT TO INDIA

By | 2017, News | No Comments

Our general director, Dr. Oscar Ahumada and business development manager, Rosalía Calleja have visited India again for a number of commercial actions.

They held an update meeting with the local representative Dr. Anand Dixit (Fourvac). Additionally they took the chance to follow up previous conversations with Solid State Physics Laboratory (SSPL) in Delhi or IIT-Kharagpur. They took also the chance to visit the Central Manufacturing Technology Institute (CMTI) located in Bangalore and give a talk to introduce our latest innovations to the audience.

New field using SCALA opened by research group headed by Prof. Carlos Alemán

By | 2016, News, Publications | No Comments

A group of researchers, Anna Puiggalí-Jou, Luis J. del Valle and Maria M. Pérez-Madrigal, headed by Prof. Carlos Alemán from Universitat Politècnica de Catalunya have just published their results with microcantilevers sensors. The paper “Weighing biointeractions between fibrin (ogen) and clot-binding peptides using microcantilever sensors” published in Journal of Peptide Science examines the biorecognition event between clotted plasma proteins and a tumor-homing pentapeptide, CR(NMe)EKA, by applying a sensing technology based on microcantilevers. The results derived from the different characterization techniques including resonance frequency measurements performed by Mecwins technology (SCALA), reflect the importance of developing emerging technologies suitable for specific medical purposes.

 

nanobiomed2016

Mecwins in NanoBio&Med 2016

By | 2016, Events, News | No Comments

Barcelona (Spain) – 22 – 24th November, 2016

Mecwins is participating in the next NanoBio&Med2016 to be held in November 22-24th in Barcelona (Spain). Our colleague Dr. Virginia Cebrian from Bioscience Department will be one of the speakers, introducing latest news and innovations of Mecwins technology at the Industrial Forum.

nanobiomed2016The NanoBio&Med conference is a perfect place to present the most recent international developments in the field of Nanobiotechnology and Nanomedicine. As organizers claim in the website of the conference “the discussion in recent advances, difficulties and breakthroughs will be at his higher level”. It will be our second year participating in the event so we can confirm such assertion.

Further information about the event by clicking here